Condition: Head & Neck Cancer · Head & Neck Squamous Cell Carcinoma · Sponsor: University of Rome Tor Vergata
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS \>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.
This description comes directly from the study's public registry record.
Vincenzo Formica, Professor · +390620908190 · vincenzo.formica@uniroma2.it
Always discuss trial participation with your own doctor first.
| Tor Vergata University Hospital | Rome, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07448727